NVCR - NASDAQ

NovoCure Limited

NVCR·NASDAQ

$16.15

+2.1%

HealthcareMedical - Instruments & Supplies

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.87B

EPS-1.2200

P/E Ratio-13.24

Earnings Date07/23/2026

804.33M

Assets

-35%

3Y-33.0%

5Y-24.0%

10Y+185.0%

463.86M

Total Liabilities

-47%

3Y-38.0%

5Y-19.0%

10Y+232.0%

340.47M

Total Equity

-5%

3Y-23.0%

5Y-29.0%

10Y+139.0%

NovoCure Limited Funding & Solvency Profile

NVCR · NASDAQ

Current Assets

Cash & Cash Equivalents103.39M

Net Receivables115.35M

Inventory0.00

Other Current Assets73.87M

Total Current Assets647 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets157.59M

Total Non-Current Assets158 M

Total Assets

804.33M

Financial Health Analysis

Current Ratio

2.90x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.36x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

424 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

80% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

NovoCure Limited Balance Sheet

NVCR • NASDAQ

NovoCure Limited Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	103.4M	163.8M	240.8M	115.3M	209.6M	246.2M	179.4M	140.6M	78.6M	99.8M	119.4M	57.6M	175.9M
Short-Term Investments	354.1M	796.1M	669.8M	854.1M	728.9M	607.9M	148.8M	105.3M	104.7M	119.9M	150M	45M	0.0
Cash & Short-Term Investments	457.5M	959.9M	910.6M	969.4M	938.5M	854.1M	328.2M	245.9M	183.3M	219.6M	269.4M	102.6M	175.9M
Net Receivables	115.3M	102.1M	77.1M	86.3M	97.4M	100.5M	64M	36.5M	29.6M	6.3M	0.0	0.0	3.9M
Accounts Receivables	89.4M	74.2M	61.2M	86.3M	93.6M	96.7M	58.9M	36.5M	29.6M	6.3M	0.0	0.0	0.0
Other Receivables	25.9M	27.8M	15.9M	0.0	3.8M	3.8M	5.1M	0.0	0.0	0.0	9.5M	4.9M	3.9M
Inventory	0.0	35.1M	38.2M	29.4M	24.4M	27.4M	23.7M	22.6M	22M	25.5M	13.6M	3.4M	1.9M
Prepaids	0.0	7.2M	6.8M	6.4M	4.7M	4M	2.3M	3.5M	2.9M	2.2M	1.5M	948K	846K
Other Current Assets	73.9M	2.3M	1.7M	20M	8.5M	13.5M	21.9M	2.1M	2.1M	267K	9.4M	4.8M	970K
Total Current Assets	646.7M	1.1B	1B	1.1B	1.1B	999.4M	439.9M	321.4M	245.1M	261.9M	293.9M	111.8M	183.5M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	119.6M	97.7M	69M	53.9M	41.6M	34.6M	15.4M	18.1M	18.6M	12.6M	5.7M	5.2M
Other Non-Current Assets	157.6M	14.6M	14M	11.2M	12.1M	10.9M	4.9M	3.1M	2.1M	1.6M	851K	297K	252K
Total Non-Current Assets	157.6M	134.2M	111.7M	80.1M	66M	52.5M	39.5M	18.4M	20.2M	20.2M	13.4M	6M	5.4M
Total Assets	804.3M	1.2B	1.1B	1.2B	1.1B	1.1B	479.4M	339.8M	265.3M	282.1M	307.3M	117.9M	188.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	122.2M	105.1M	94.4M	85.2M	78.4M	59M	48.9M	26.7M	26.3M	21.5M	16.8M	10M	10.3M
Accounts Payable	122.2M	105.1M	94.4M	85.2M	72.6M	53.6M	36.9M	26.7M	17.2M	18.4M	13.9M	10M	10.3M
Other Payables	0.0	0.0	0.0	0.0	5.8M	5.3M	12M	0.0	9.1M	3.1M	2.9M	0.0	0.0
Accrued Expenses	64.4M	71M	68.5M	55.6M	39.6M	30.3M	20.9M	16.7M	13.3M	7.5M	8.3M	5.8M	4.9M
Short Term Debt	11.7M	558.2M	0.0	0.0	6.7M	6.5M	4.6M	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	7.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	9.1M	8.7M	5.8M	5.3M	12M	12.3M	9.1M	3.1M	2.9M	693K	384K
Deferred Revenue	15.9M	14.2M	16.2M	18M	17.8M	17.8M	11.8M	8.8M	5M	2.3M	0.0	0.0	0.0
Other Current Liabilities	9M	0.0	0.0	0.0	169K	61K	64K	12.3M	5.6M	5.6M	3.6M	1.8M	445K
Total Current Liabilities	223.2M	756.4M	179.1M	158.8M	142.6M	113.6M	86.3M	64.6M	50.2M	36.9M	28.6M	17.7M	15.6M
NON-CURRENT LIABILITIES
Long Term Debt	236.7M	97.3M	568.8M	565.5M	562.2M	429.9M	149.4M	149.3M	97.3M	96.2M	23.1M	321K	346K
Deferred Revenue (Non-Current)	0.0	0.0	0.0	2.9M	6.5M	12.1M	7.8M	9.9M	0.0	906K	785K	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	124K	0.0	-906K	-785K	0.0	0.0
Other Non-Current Liabilities	-37.7M	7M	8.3M	4.6M	4.7M	5.5M	4M	3.7M	4.2M	6.6M	4.8M	2M	1.2M
Total Non-Current Liabilities	240.6M	124.2M	604.5M	591.7M	586.4M	461.8M	175.3M	163M	101.5M	102.9M	27.9M	2.3M	1.5M
Capital Lease Obligations	41.6M	27.9M	27.4M	18.8M	13M	14.3M	14.1M	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	463.9M	880.6M	783.6M	750.5M	729M	575.5M	261.7M	227.5M	151.7M	139.7M	56.5M	20M	17.1M
SHAREHOLDERS' EQUITY
Additional Paid-In Capital	1.6B	1.5B	1.4B	1.2B	1.1B	1.1B	871.4M	757.3M	697.2M	664.2M	640.4M	374.4M	367.6M
Retained Earnings	-1.3B	-1.2B	-985.5M	-778.5M	-685.9M	-631.1M	-650.9M	-643.7M	-582.3M	-519.9M	-388.1M	-276.5M	-195.8M
Accumulated Other Comprehensive Income/Loss	-3.4M	-5.5M	-5.5M	-2.4M	-3.2M	-3.8M	-2.8M	-1.4M	-1.3M	-1.9M	-1.5M	-4.3M	-2.4M
Total Stockholders' Equity	340.5M	360.2M	362.5M	441.2M	410.5M	476.5M	217.8M	112.3M	113.6M	142.3M	250.8M	97.9M	171.8M
Total Equity	340.5M	360.2M	362.5M	441.2M	410.5M	476.5M	217.8M	112.3M	113.6M	142.3M	250.8M	97.9M	171.8M
SUMMARY
Total Liabilities & Equity	804.3M	1.2B	1.1B	1.2B	1.1B	1.1B	479.4M	339.8M	265.3M	282.1M	307.3M	117.9M	188.9M
Total Investments	354.1M	796.1M	669.8M	854.1M	728.9M	607.9M	148.8M	105.3M	104.7M	119.9M	150M	45M	0.0
Total Debt	290M	683.4M	596.2M	584.3M	581.9M	450.7M	168.2M	149.3M	97.3M	96.2M	23.1M	321K	346K
Net Debt	186.6M	519.6M	355.4M	468.9M	372.3M	204.5M	-11.2M	8.6M	18.8M	-3.5M	-96.3M	-57.3M	-175.5M
Shares Outstanding	115,820,940	115,820,940	115,820,940	115,820,940	115,820,940	115,820,940	115,820,940	115,820,940	115,820,940	115,820,940	115,820,940	115,820,940	115,820,940

SEC Filings

NVCR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	April 30, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
8-K/A 8-K/A 2025 (Amended) N/A	April 24, 2026	November 24, 2025	2025	View Filing
DEF 14A DEF 14A 2026 N/A	April 20, 2026	June 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 09, 2026	April 08, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 26, 2026	March 26, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 24, 2026	February 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 11, 2026	February 11, 2026	2026	View Filing

Showing 1 to 10 of 211 filings

Related Guides

Blog Categories

Continue your NVCR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.